We observed that RSPO2 and its receptor, GPR48/LGR4, were expressed in normal thyroid gland and at higher levels in in PTCs, particularly in patients with regional tumor progression, including lymph node (LN) metastasis. Here, RSPO2 is linked to neoplasm.